OPIOID PREPARATION HAVING EXTENDED RELEASE INHIBITING PROPERTIES

Publication number: JP7145056 (A)
Publication date: 1995-06-06
Inventor(s): SACKLER RICHARD [US]; GOLDENHEIM PAUL [US]; KAIKO ROBERT [US]; OSHLACK BENJAMIN [US]; CHASIN MARK [US]; PEDI FRANK [US]
Applicant(s): EURO CELTIQUE SA [LU]
Classification:
- international: ***A61K9/52; A61K9/16; A61K9/20; A61K9/22; A61K9/28; A61K9/50; A61K31/445; A61K31/485; A61K31/522; A61K47/32; A61K47/36; A61K47/38; A61K47/42; A61K47/44; A61P25/04;*** **A61K9/52; A61K9/16; A61K9/20; A61K9/22; A61K9/28; A61K9/50; A61K31/445; A61K31/485; A61K31/519; A61K47/32; A61K47/36; A61K47/38; A61K47/42; A61K47/44; A61P25/00;** (IPC1-7): A61K31/485; A61K9/52; A61K31/445; A61K47/32; A61K47/38; A61K47/42; A61K47/44
- European: A61K9/16H4; A61K9/16H6B; A61K9/20H4; A61K9/20H6F2; A61K9/20K; A61K9/20K2B; A61K9/20P; A61K9/28H6F2; A61K9/50K2; A61K31/485; A61K31/522
Application number: JP19940150938 19940701
Priority number(s): US19930086248 19930701

Also published as:
JP3645589 (B2)
EP0631781 (A1)
ZA9404773 (A)
ZA9404599 (A)
TW450814 (B)
more >>

Abstract of **JP 7145056 (A)**

PURPOSE: To obtain an opioid preparation capable of controlling the release rate of an active ingredient contained in the solid sustained release type oral administration preparation, and capable of maintaining the activity of the medicine and simultaneously elongating a period for moderating the pain of an injected patient to decrease the number of the administrations. CONSTITUTION: This solid sustained release type oral administration preparation comprises a therapeutically effective dose of an opioid analgesic or its salt.; The dissolution rate of the administration preparation in vitro is selected so as to release about 12.5-42.5 wt.% of the active ingredient (opioid analgesic) after 1 hr, release about 45-85 wt.% of the active ingredient after 4 hr, release an amount above about 60 wt.% after 8 hr, when the dissolution rate is measured using 900 ml of an aqueous buffer solution at 37 deg.C at 100 rpm by a paddle method in USP. The release rate in vitro is substantially independent from pH, and the maximum plasma level of the active reagent is selected to generate within about 2-8 hr after the administration of the preparation, thus elongating a period of about 24 hr for releasing the patient from the pain.